BioPharmSignal logoBioPharmSignal

Biotech News

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

Eagle Pharmaceuticals (EGRX)Eagle Pharmaceuticals2026-06-25 13:46 ESTCompany update

WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended,

Open original release

Related news

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Eagle Pharmaceuticals

Eagle Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

EGRXEagle Pharmaceuticals2026-06-26 10:40 EST

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2026-06-26 10:40 EST

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

EGRXEagle Pharmaceuticals2026-06-26 10:40 EST

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

EGRXEagle Pharmaceuticals2026-06-26 10:40 EST

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

EGRXEagle Pharmaceuticals2026-06-26 10:40 EST

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States